Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection or Disease or with Concurrent Organ...

Area of Science:

• Infectious Diseases
• Transplantation Immunology
• Pharmacology

Background:

• Refractory or resistant cytomegalovirus (CMV) infection presents a significant clinical challenge, particularly in immunocompromised individuals such as solid organ transplant (SOT) and allogeneic hematopoietic cell transplant (allo-HCT) recipients.
• Effective treatment options for CMV in these vulnerable patient populations are crucial to prevent disease progression and improve outcomes.

Purpose of the Study:

• To evaluate the safety and efficacy of letermovir for treating cytomegalovirus (CMV) infection or disease in immunocompromised patients.
• To assess virological and clinical responses to letermovir treatment in patients with refractory or resistant CMV or CMV with concurrent organ dysfunction.

Main Methods:

• An open-label, phase II, non-randomized clinical trial was conducted.
• Eligible participants included adult and pediatric (≥12 years) SOT or allo-HCT recipients requiring antiviral treatment for refractory/resistant CMV or with CMV and organ dysfunction.
• Patients received daily letermovir for up to 12 weeks, with an option for secondary prophylaxis.

Main Results:

• Ten patients were enrolled; seven completed the study. The overall virological response rate was 60%.
• Letermovir was generally well tolerated, with only two patients experiencing drug-related toxicity (one Grade 3 elevated ALT).
• No significant adverse events such as acute kidney injury, hepatotoxicity, cardiac arrhythmias, or bone marrow suppression were observed.

Conclusions:

• Letermovir appears to be a safe and well-tolerated treatment option for CMV in this limited cohort of immunocompromised patients.
• Further investigation is warranted to establish the definitive role of letermovir in treating refractory or resistant CMV infections and disease.